HUTCHMED (China) Ltd
ORPATHYS
MET-amplified gastric cancer
Resolved
5days ago
Approval decision · Jul 2, 2026
What's at stake
A final FDA approval decision on ORPATHYS for MET-amplified gastric cancer is expected Jul 2, 2026.
Primary source
· SEC 6-K
verified 13h ago
“HUTCHMED Announces NMPA Approval for ORPATHYS for the treatment of Gastric Cancer Patients with MET Amplification”